Amarin Corp. PLC ADR (AMRN) News
Filter AMRN News Items
AMRN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AMRN News Highlights
- For AMRN, its 30 day story count is now at 9.
- Over the past 22 days, the trend for AMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about AMRN are PLUG and COOL.
Latest AMRN News From Around the Web
Below are the latest news stories about Amarin Corp Plc that investors may wish to consider to help them evaluate AMRN as an investment opportunity.
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and ReimbursementDUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional engagement through a new omnichannel platform, enhancing managed care access and optimizing VA |
Amarin to Participate in September Investment ConferencesDUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021. H. C. |
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in GermanyBrings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy |
5 Stocks With 195% to 467% Upside, According to Wall StreetIf the high-water price target for each of the following five stocks were to come to fruition, shareholders would be looking at gains ranging from a low of 195% to as much as 467%. If you're "only" looking to triple your money, analyst Amit Dayal of H.C. Wainwright would suggest putting it to work in hydrogen fuel-cell solutions company Plug Power (NASDAQ: PLUG). Dayal's price target of $78 implies a cool 195% upside from where its shares closed this past weekend. |
Atossa Therapeutics Has a Steep Climb Ahead of ItAtossa Therapeutics is popular with the Reddit crowd. |
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of CardiologyVASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction |
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of CardiologyVASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients with prior heart attack, known as myocardial infarction (MI), at risk for major adverse cardiovascular |
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of CardiologyAmarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven PresentationsDUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular events will be presented at ESC Congress 2021, organized by the European Society of Cardiology (ESC), being h |
Amarin Corporation plc's (NASDAQ:AMRN) Stock Is Going Strong: Have Financials A Role To Play?Amarin's (NASDAQ:AMRN) stock is up by a considerable 19% over the past week. As most would know, fundamentals are what... |
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite GenericsAmarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up. |